A multicentre longitudinal study revealed that the effective control of inflammation, namely, the use of TNF-α inhibitors, reduces cardiovascular risk in patients with IBD, as evidenced by a reduction in aortic pulse wave velocity, which was used as a surrogate indicator of cardiovascular risk [86]. This evidence concerns the gene TNF and inflammatory bowel disease.